Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

Highlights include clinical data from Phase 3 studies in Community Acquired Pneumonia (CABP) and microbiologic data from a Phase 2 study in ...
PHILADELPHIA.Today

Merck Finalizes $10 Billion Acquisition, Expands COPD Treatment Portfolio

Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.